个人简介

EducationPh.D. Department of Biochemistry, The Chinese University of Hong KongM.Sc. College of Life Sciences, Jilin UniversityB.Sc. College of Life Sciences, Jilin UniversityAcademic and Professional Experience2016-present Assistant Professor, Faculty of Health Sciences, University of Macau2013-2016 Principle Investigator, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences2011-2013 Research Associate, Memorial Sloan-Kettering Cancer Center2008-2011 Postdoctoral Fellow, National Cancer Institute, NIH

研究领域

Our group is interested in the development of antibody-based therapeutics for cancer. The research focuses on engineering of monoclonal antibodies, bispecific antibodies, or chimeric antigen receptors (CARs) to treat tumors. We identify novel human monoclonal antibodies from antibody phage libraries. Monoclonal antibodies typically IgGs can destroy tumor cells by utilizing mechanisms of antibody-dependent cellular cytotoxicity (ADCC) or antibody-drug conjugation (ADC). By using these antibodies as vehicles, bispecific antibodies directed at tumor antigens and human CD3 can engage T cells to lyse tumors. Additionally, all of these antibodies can be reshaped to build CAR to redirect T cells.Areas of Expertise:(1) antibody engineering; (2) CAR-modified T cells ; (3) antibody-drug conjugation; (4) phage and yeast display libraries

近期论文

Zhu L, Liu J, Zhou G, Wu X, Ang IL, Ma G, Liu Y, Yang S, Zhang F, Miao K, Poon TCW, Zhang X, Yuan Z, Deng C, Zhao Q. Targeting Immune Checkpoint B7-H3 Antibody-Chlorin e6 Conjugates for Spectroscopic Photoacoustic Imaging and Photodynamic Therapy. Chemical Communications. 2019;55(95):14255-14258.Zhao Q. Novel chimeric antigen receptor T cells based on T-cell receptor-like antibodies. Blood Sciences. 2019;1(2):144-147.Zhu L, Li P, Gao D, Liu J, Liu Y, Sun C, Xu M, Chen X, Sheng Z, Wang R, Yuan Z, Cai L, Ma Y, Zhao Q. pH-sensitive loaded retinal/indocyanine green micelles as a “all-in-one” theranostic agent for multi-modal imaging in vivo guided cellular senescence-photothermal synergistic therapy. Chemical Communications. 2019;55(44):6209-6212.Huang S, Yang J, Fong S, Zhao Q. Mining Prognosis Index of Brain Metastases Using Artificial Intelligence. Cancers. 2019;11(8):1140.Huang S, Zhao Q. Nanomedicine-combined immunotherapy for cancer. Current Medicinal Chemistry. 2019;26:1.Hu D, Zhu Z, Li S, Deng Y, Wu Y, Zhang N, Puri V, Wang C, Zou P, Lei C, Tian X, Wang Y, Zhao Q, Li W, Prabakaran P, Feng Y, Cardosa J, Qin C, Zhou X, Dimitrov DS, Ying T. A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III. PLoS Pathogens. 2019 Jun 26;15(6):e1007836.Liu J, Zhou G, Zhang L, Zhao Q. Building potent chimeric antigen receptor T cells with CRISPR genome editing. Frontiers in Immunology. 2019;10:456.Huang S, Fong CI, Xu M, Han B, Yuan Z, Zhao Q. Nano-loaded natural killer cells as carriers of ICG for synergetic cancer immunotherapy and phototherapy. Journal of Innovative Optical Health Sciences. 2019;12(03):1941002.Wang Y, Shan Y, Gao X, Gong R, Zheng J, Zhang XD, Zhao Q. Screening and expressing HIV-1 specific antibody fragments in Saccharomyces cerevisiae. Molecular immunology. 2018;103: 279-285.Gao H, Huang S, Du J, Zhang X, Jiang N, Kang W, Mao J, Zhao Q. Comparison of Prognostic Indices in NSCLC Patients with Brain Metastases after Radiosurgery. International Journal of Biological Sciences. 2018;14(14):2065-2072.Wu Y, Chen Z, Zhang P, Zhou L, Jiang T, Chen H, Gong P, Dimitrov DS, CaiL, Zhao Q. Recombinant-fully-human-antibody decorated highly-stable far-red AIEdots for in vivo HER-2 receptor-targeted imaging. Chemical Communications. 2018;54(53):7314-7317.Li D, Yao G, Han B, Liu J, Su W, Wang P, Zhu Z, Dimitrov DS, Zhao Q. N-terminal α-amino group modification of antibodies using a site-selective click chemistry method. mAbs. 2018;10(5):712-719.Hao D, Liu J, Chen M, Li J, Wang L, Wang G, Zhao Q, Di LJ. Immunogenomic analyses of advanced serous ovarian cancer reveal immune score is a strong prognostic factor and an indicator of chemo-sensitivity. Clin Cancer Res. 2018;24(15):3560-3571.Chen Z, Liu J, Chu D, Ma G, Zhang H, Shan Y, Chen Q, Deng C, Chen W, Dimitrov DS, Zhao Q. A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells. International Journal of Biological Sciences. 2018;14(7):799-806.Xie R, Zhang X, Zhao Q, Peng B, Zheng J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerging Microbes & Infections 2018;7:31.XuY，Li P, Nie J, Zhao Q, Guan S, Kuai, Qiao Y, Jiang X, Li Y, Li W, Shi Y, Kong W, Shan Y. Humanization and directed evolution of the selenium-containing scFv phage abzyme. RSC Adv. 2018;8:17218-17223.Xu T, Ying T, Wang L, Zhang X, Wang Y, Kang L, Huang T, Cheng L, Wang L, Zhao Q. A native-like bispecific antibody suppresses the inflammatory cytokine response by simultaneously neutralizing tumor necrosis factor-alpha and interleukin-17A. Oncotarget. 2017;8(47):81860-81872.Chu D, Dong X, Zhao Q, Gu J, Wang Z. Photosensitization priming of tumor microenvironments improves delivery of nanotherapeutics via neutrophil infiltration. Advanced Materials. 2017;29(27).Li D, Gong R, Zheng J, Chen X, Dimitrov D, Zhao Q. Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation. Biochemical and Biophysical Research Communications. 2017;485(2):446-453.Chen Z, Wang L, Xu T, Wang Q, Kang L, Zhao Q. Generation of bispecific antibodies by Fc heterodimerization and their application. Current Pharmaceutical Biotechnology. 2016;17:1324-1332.